Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Half of patients treated with the customized T cells achieved complete remission.
A unique analysis measures treatment-free survival after immunotherapy in patients with advanced renal cell carcinoma.
Targeted therapies are available for eight tumor mutations, highlighting the importance of genomic testing.
There’s no FDA-approved treatment for uveal, or eye, melanoma, but a new immunotherapy and molecular therapy show encouraging results.
Immunotherapy plus chemotherapy improved overall survival in people with persistent, recurrent or metastatic cervical cancer.
New patient/caregiver resource from the National Comprehensive Cancer Network focuses on small cell lung cancer, an aggressive cancer.
Patricia Janiak learned how to ask the tough questions when her husband was diagnosed with mucosal melanoma.
Imfinzi plus chemotherapy led to a modest but significant improvement in overall survival.
At Melanoma Research Alliance’s 2021 Scientific Treat, scientists discussed enhancing anti-tumor immune response of combination therapies.
Data from early clinical trials suggest new precision cancer treatments are on the horizon.
The antibody-drug conjugate Tivdak led to remission in 24% of cervical cancer patients.
Third booster dose may improve immune response in cancer patients without sufficient protection after second dose.
Keytruda plus chemotherapy reduced the risk of death by 27% in people with locally advanced or metastatic disease.
Opdivo plus relatlimab delayed disease progression compared with Opdivo alone.
Many older people have biomarkers indicative of a strong response to checkpoint inhibitors.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.